This activity has been accredited for 0.75 Group 1 CPD credits suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 1.5 Group 2 CPD credits upon successful completion of relevant assessment activities.
Clinical research over the last three decades continues to demonstrate that probiotics and prebiotics can contribute to the development of a healthy gut, which is associated with improved immune function, intestinal and metabolic health as well as quality of life; with positive influences on end organ physiology (e.g., liver, brain). As research progresses it is imperative that probiotics NOT be seen as a panacea to ameliorate all chronic diseases and that research with probiotic formulations that are clinically tested should inform on efficacy or otherwise in different clinical scenarios. What we do know is that probiotics and prebiotics can help achieve significant clinical benefits when prescribed and administered as part of a lifestyle program, and perhaps also when prescribed as an adjunctive medicine with standard pharmaceutical products.
Luis Vitetta is a Professor with the University of Sydney, Faculty of Medicine and Health in the School of Medicine and is Director of Medical Research at Medlab Clinical in Sydney. Between the years 2007–2013 he was the Director and Professor of the Centre for Integrative Clinical and Molecular Medicine at The University of Queensland, Faculty of Medicine, based at the Princess Alexandra Hospital in Brisbane. Luis has research interests in the microbiome/nutrition/probiotics and mucosal and cellular immunity as well as medicinal cannabis.
Medlab‘s focus is on the gut microbiome and its connection with various chronic diseases, as research into the microbiome, is crucial for developing effective probiotics to mitigate disease. Research into the link between the microbiome and mental disorders like depression is a very exciting and promising area that Medlab is pursuing, with human patients currently being recruited for Phase IIA clinical trials of NRGBiotic™. Medlab is also researching and developing probiotic applications for the treatment and management of diabetes and chronic kidney disease.